Reactions 1112 - 29 Jul 2006

★ S

Etodolac

First report of depressed-type colorectal cancer:

case report

A 61-year-old man developed depressed-type early invasive

colorectal cancer during treatment with etodolac for knee joint

pain.

The man presented with multiple colorectal polyps and

underwent resection of all polyps > 5mm in size, while

polyps ≤ 5mm were left in his colon and rectum. During an

outpatient follow-up, he started receiving etodolac [Hypen]

200mg twice daily and, 6 months later, a follow-up

colonoscopy showed six polyps, which had decreased in size,

and a depressed-type lesion (5mm in size) in his distal

transverse colon. A chromoendoscopy with magnification

showed a type III-type pit pattern in his depressed area. Based

on his endoscopic findings, his lesion was estimated to be a

cancer, which was limited within his mucosal layer or slightly

invading his submucosal layer.

The man underwent an endoscopic mucosal resection and

his lesion was completely resected. A histopathological

analysis showed well-differentiated adenocarcinoma slightly

invading the submucosal layer and without adenomatous

components. Follow-up colonoscopies showed no recurrence.

Kaihara T, et al. Depressed-type early invasive colon cancer in a patient treated

with cyclooxygenase-2 inhibitor. Digestive Diseases and Sciences 51: 885-888, No.

5, May 2006 - Japan

801041692

» Editorial comment: A search of AdisBase and Medline did

not reveal any previous case reports of depressed-type

colorectal cancer associated with etodolac. The WHO Adverse

Drug Reactions database contained no reports of colon

carcinoma or rectal carcinoma associated with etodolac.